<DOC>
	<DOCNO>NCT00002662</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether paclitaxel effective docetaxel breast cancer . PURPOSE : Randomized phase III trial study effectiveness paclitaxel docetaxel treat woman stage IIIB metastatic breast cancer .</brief_summary>
	<brief_title>Paclitaxel Docetaxel Treating Women With Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare response rate woman metastatic locally advanced , inoperable adenocarcinoma breast treat docetaxel v paclitaxel . - Compare toxicity regimens patient . - Compare time disease progression , duration response , quality life , survival patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive docetaxel IV 1 hour day 1 . Courses repeat every 3 week absence disease progression unacceptable toxicity . - Arm II : Patients receive paclitaxel IV 3 hour day 1 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Quality life assess baseline course 4 6 . Patients follow every 3 month . PROJECTED ACCRUAL : A total 400 patient ( 200 per arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic locally advanced , inoperable adenocarcinoma breast Clinically evident metastasis ( e.g. , clearly malignant lesion chest xray CT abdominal CT require histologic confirmation ) Hot spot bone scan show malignant plain xrays adequate evidence malignant disease absence lesion Must meet 1 follow condition : Disease progression 1 prior chemotherapy regimen locally advance metastatic disease ( may may follow separate adjuvant regimen use chemotherapy hormonal therapy ) Locally advanced metastatic disease 1 adjuvant neoadjuvant chemotherapy regimen One chemotherapy regimens must contain anthracycline ( e.g. , doxorubicin , mitoxantrone ) Single drug substitution ( e.g. , methotrexate doxorubicin ) prior combination chemotherapy allow Bidimensionally measurable No clinical radiographic evidence brain leptomeningeal disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : Karnofsky 60100 % OR ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal SGOT great 2.5 time upper limit normal Renal : Creatinine great 2.0 mg/dL No uncontrolled hypercalcemia Cardiovascular : No myocardial infarction within past 6 month No history arrhythmia require treatment No heart block No clinical evidence congestive heart failure No unstable angina ( e.g. , new onset , crescendo , rest angina ) Stable exertional angina allow Other : No current symptomatic grade 2 great peripheral neuropathy No history hypersensitivity product contain Cremophor EL ( e.g. , cyclosporine teniposide ) Polysorbate 80 ( e.g. , IV etoposide ) No serious infection No significant psychiatric disease would preclude study No malignancy within past 5 year except nonmelanomatous skin cancer completely excise carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow stem cell transplantation Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ( 2 week oral cyclophosphamide 6 week nitrosoureas mitomycin ) No prior highdose chemotherapy give ablative intent No prior taxoids No concurrent antineoplastic therapy Endocrine therapy : See Disease Characteristics Prior hormonal therapy adjuvant therapy metastatic disease allow At least 1 week since prior hormonal therapy No concurrent corticosteroid except : Prophylaxis treatment acute hypersensitivity reaction Chronic therapy ( 6 month ) low dos ( 20 mg/day less methylprednisolone equivalent ) Radiotherapy : At least 4 week since prior radiotherapy major bone marrow area No prior highdose radiotherapy give ablative intent No concurrent radiotherapy except limited palliative radiotherapy ( e.g. , solitary rib fracture ) objective response Surgery : See Disease Characteristics More 2 week since prior surgery except simple biopsy placement venous access device Other : At least 4 week since prior investigational drug Concurrent medication know alter cardiac conduction ( e.g. , digoxin , beta blocker , calcium channel blocker ) allow No concurrent ketoconazole No concurrent bisphosphonates unless initiate 3 month randomization No concurrent experimental drug therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>